Swallow, Carol J.
Strauss, Dirk C.
Bonvalot, Sylvie
Rutkowski, Piotr
Desai, Anant
Gladdy, Rebecca A.
Gonzalez, Ricardo
Gyorki, David E.
Fairweather, Mark
van Houdt, Winan J.
Stoeckle, Eberhard
Park, Jae Berm
Albertsmeier, Markus
Nessim, Carolyn
Cardona, Kenneth
Fiore, Marco
Hayes, Andrew
Tzanis, Dimitri
Skoczylas, Jacek
Ford, Samuel J.
Ng, Deanna
Mullinax, John E.
Snow, Hayden
Haas, Rick L.
Callegaro, Dario
Smith, Myles J.
Bouhadiba, Toufik
Stacchiotti, Silvia
Jones, Robin L.
DeLaney, Thomas
Roland, Christina L.
Raut, Chandrajit P.
Gronchi, Alessandro
,
Article History
Received: 2 November 2020
Accepted: 11 January 2021
First Online: 14 April 2021
Disclosure
: Piotr Rutkowski has received honoraria for lectures and advisory boards from Novartis, BMS, MSD, Pierre Fabre, Blueprin Medicines, Pfizer, Sanofi, and Merck outside the scope of this manuscript. Silvia Stacchiotti reports personal financial interests (honoraria, consultancy or advisory role) from Adaptimmune, Bayer, Epizyme, Eli Lilly, Daiichi Sankyo, Deciphera, Immunedesign, Karyopharm, Maxivax, Novartis, Pharmamar, and Takeda; and institutional financial interests from Advenchen, Amgen Dompé, Bayer, Epizyme, Eli Lilly, Daiichi Sankyo, Karyopharm, Novartis, Pfizer, Pharmamar, and Springwork. Robin Jones is a consultant and/or advisor for Adaptimmune Therapeutics plc.; Athenex Inc.; Bayer; Blueprint Medicines; Boehringer Ingelheim Clinigen Group plc.; Daiichi Sankyo Company, Limited; Deciphera Pharmaceuticals Ltd.; Eisai Co., Ltd.; Eli Lilly and Company; Epizyme, Inc.; Immune Design Corp; Merck Sharp & Dohme; Pharma Mar S.A; and UpToDate, Inc. Carol J. Swallow, Dirk Strauss, Sylvie Bonvalot, Anant Desai, Rebecca A. Gladdy, Ricardo Gonzalez, David E. Gyorki, Mark Fairweather , Winan J. van Houdt, Eberhard Stoeckle, Jae Berm Park, Markus Albertsmeier, Carolyn Nessim, Kenneth Cardona, Marco Fiore, Andrew Hayes, Dimitri Tzanis, Jacek Skoczylas, Samuel J. Ford, Deanna Ng, John E. Mullinax, Hayden Snow, Rick L. Haas, Dario Callegaro, Myles J. Smith, Toufik Bouhadiba, Thomas DeLaney, Christina L. Roland, Chandrajit P. Raut, and Alessandro Gronchi have no conflicts of interest to declare.